IL318499A - תרכובות לפירוק ליזוזומלי ממוקד ושיטות שימוש בהן - Google Patents
תרכובות לפירוק ליזוזומלי ממוקד ושיטות שימוש בהןInfo
- Publication number
- IL318499A IL318499A IL318499A IL31849925A IL318499A IL 318499 A IL318499 A IL 318499A IL 318499 A IL318499 A IL 318499A IL 31849925 A IL31849925 A IL 31849925A IL 318499 A IL318499 A IL 318499A
- Authority
- IL
- Israel
- Prior art keywords
- degradaton
- compositions
- methods
- lysosomal
- targeted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263369948P | 2022-07-30 | 2022-07-30 | |
| US202263423454P | 2022-11-07 | 2022-11-07 | |
| PCT/US2023/028967 WO2024030341A1 (en) | 2022-07-30 | 2023-07-28 | Compositions for targeted lysosomal degradaton and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL318499A true IL318499A (he) | 2025-03-01 |
Family
ID=87800758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL318499A IL318499A (he) | 2022-07-30 | 2023-07-28 | תרכובות לפירוק ליזוזומלי ממוקד ושיטות שימוש בהן |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4562042A1 (he) |
| JP (1) | JP2025525096A (he) |
| KR (1) | KR20250044738A (he) |
| CN (1) | CN120019076A (he) |
| AU (1) | AU2023317484A1 (he) |
| CA (1) | CA3263050A1 (he) |
| IL (1) | IL318499A (he) |
| MA (1) | MA71625A (he) |
| MX (1) | MX2025001285A (he) |
| WO (1) | WO2024030341A1 (he) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119350297B (zh) * | 2024-12-25 | 2025-04-04 | 浙江大学 | 一种特异性溶酶体靶向嵌合体分子及其制备方法和应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005522514A (ja) | 2002-04-10 | 2005-07-28 | ジェネンテック・インコーポレーテッド | 抗ｈｅｒ２抗体改変体 |
| US7476724B2 (en) | 2004-08-05 | 2009-01-13 | Genentech, Inc. | Humanized anti-cmet antibodies |
| GB0503546D0 (en) | 2005-02-21 | 2005-03-30 | Hellenic Pasteur Inst | Antibody |
| EP1945674A2 (en) | 2005-11-03 | 2008-07-23 | Genentech, Inc. | Therapeutic anti-her2 antibody fusion polypeptides |
| UA96139C2 (uk) * | 2005-11-08 | 2011-10-10 | Дженентек, Інк. | Антитіло до нейропіліну-1 (nrp1) |
| WO2008076257A2 (en) | 2006-12-13 | 2008-06-26 | Schering Corporation | Treating cancer with anti-igflr antibody 19d12 = sch 717454 |
| US9469691B2 (en) | 2008-12-02 | 2016-10-18 | Pierre Fabre Medicament | Anti-cMET antibody |
| WO2010064089A1 (en) | 2008-12-02 | 2010-06-10 | Pierre Fabre Medicament | Novel anti-cmet antibody |
| US20140112911A9 (en) | 2008-12-02 | 2014-04-24 | Liliane Goetsch | Novel anti-cmet antibody |
| US20110313137A1 (en) | 2009-02-25 | 2011-12-22 | Dongxing Zha | Her2 antibody compositions |
| EP2287197A1 (en) | 2009-08-21 | 2011-02-23 | Pierre Fabre Medicament | Anti-cMET antibody and its use for the detection and the diagnosis of cancer |
| WO2011057064A1 (en) | 2009-11-05 | 2011-05-12 | Brian Long | Igf1r inhibitor based treatment of prostate cancer |
| CN102167742B (zh) | 2010-02-25 | 2014-05-14 | 上海百迈博制药有限公司 | 一种全人源抗her2单克隆抗体、其制备方法及用途 |
| JP6055312B2 (ja) | 2010-03-10 | 2017-01-11 | ゲンマブ エー／エス | Ｃ−ｍｅｔに対するモノクローナル抗体 |
| JP2014516964A (ja) | 2011-05-18 | 2014-07-17 | メルク・シャープ・アンド・ドーム・コーポレーション | 治療用抗ｉｇｆ１ｒ合剤 |
| CN102492039B (zh) | 2011-11-21 | 2015-03-11 | 无锡天演生物技术有限公司 | 全人源抗人her2单抗 |
| US10519245B2 (en) | 2012-06-21 | 2019-12-31 | Sorrento Therapeutics Inc. | Antibodies which bind insulin-like growth factor receptor-1 (IGF1R) and methods of use thereof to treat cancer |
| AU2014385800B2 (en) | 2014-03-06 | 2020-10-22 | National Research Council Of Canada | Insulin-like growth factor 1 receptor -specific antibodies and uses thereof |
| CN106459194B (zh) | 2014-03-06 | 2019-10-18 | 加拿大国家研究委员会 | 胰岛素样生长因子1受体特异性抗体及其用途 |
| US9975960B2 (en) | 2014-05-09 | 2018-05-22 | Samsung Electronics Co., Ltd. | Anti-HER2 antibody and anti-c-Met/anti-HER2 bispecific antibodies comprising the same |
| EP3310812B1 (en) | 2015-06-17 | 2025-07-30 | F. Hoffmann-La Roche AG | Anti-her2 antibodies and methods of use |
| WO2017171373A2 (ko) * | 2016-03-29 | 2017-10-05 | 아주대학교산학협력단 | Egfr 표적 제제에 대한 저항성을 억제하기 위한 조성물 |
| US10167342B2 (en) | 2016-08-29 | 2019-01-01 | Fazel Shokri | Production of hersintuzumab: a new humanized antibody against HER2 for cancer treatment |
| EP3512882B1 (en) | 2016-09-14 | 2021-03-10 | Merck Patent GmbH | Anti-c-met antibodies and antibody drug conjugates thereof for efficient tumor inhibition |
| JP2020517659A (ja) * | 2017-04-24 | 2020-06-18 | イクノス サイエンシズ エスエー | Ｅｇｆｒ陽性癌の治療のためのｔ細胞リダイレクト二重特異性抗体 |
| WO2020079280A1 (en) * | 2018-10-19 | 2020-04-23 | Ichnos Sciences SA | T cell redirecting bispecific antibodies for the treatment of squamous cell cancers |
| CR20240462A (es) * | 2022-03-30 | 2024-12-11 | Pinetree Therapeutics Inc | Anticuerpos biespecíficos que comprenden un dominio de unión a nrp1 y métodos de uso de los mismos |
-
2023
- 2023-07-28 MA MA71625A patent/MA71625A/fr unknown
- 2023-07-28 CA CA3263050A patent/CA3263050A1/en active Pending
- 2023-07-28 JP JP2025505397A patent/JP2025525096A/ja active Pending
- 2023-07-28 EP EP23761268.4A patent/EP4562042A1/en active Pending
- 2023-07-28 IL IL318499A patent/IL318499A/he unknown
- 2023-07-28 KR KR1020257006673A patent/KR20250044738A/ko active Pending
- 2023-07-28 WO PCT/US2023/028967 patent/WO2024030341A1/en not_active Ceased
- 2023-07-28 CN CN202380069681.4A patent/CN120019076A/zh active Pending
- 2023-07-28 AU AU2023317484A patent/AU2023317484A1/en active Pending
-
2025
- 2025-01-30 MX MX2025001285A patent/MX2025001285A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4562042A1 (en) | 2025-06-04 |
| MX2025001285A (es) | 2025-03-07 |
| WO2024030341A1 (en) | 2024-02-08 |
| WO2024030341A9 (en) | 2025-02-13 |
| KR20250044738A (ko) | 2025-04-01 |
| JP2025525096A (ja) | 2025-08-01 |
| CN120019076A (zh) | 2025-05-16 |
| AU2023317484A1 (en) | 2025-03-13 |
| MA71625A (fr) | 2025-05-30 |
| CA3263050A1 (en) | 2024-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2605312B (en) | Compositions and methods for delivery of RNA | |
| IL309952A (he) | הרכבים ושיטות לטיפול במלנומה | |
| IL308221A (he) | תכשירים ושיטות לטיפול בדיכאון | |
| EP4121224A4 (en) | CLEANING COMPOSITIONS AND METHODS OF USE THEREOF | |
| IL304123A (he) | תכשירים ושיטות להעברה של rna | |
| EP4110369A4 (en) | TREATMENT METHODS AND RELATED COMPOSITIONS | |
| IL324625A (he) | הרכבים משפרי שינה ושיטות לשימוש | |
| GB202319843D0 (en) | CAS13-based compositions and methods of use thereof | |
| GB202419127D0 (en) | Compositions and methods for the targeting of pcsk9 | |
| EP4204506A4 (en) | CLEANING COMPOSITIONS AND METHODS OF USE | |
| EP4381022A4 (en) | COMPOSITIONS AND METHODS OF USE THEREOF | |
| IL318499A (he) | תרכובות לפירוק ליזוזומלי ממוקד ושיטות שימוש בהן | |
| IL325551A (he) | הרכבים ושיטות לשימוש בתצמידי נוגדנים-אוליגונקליאוטידים ממוקדי- pln | |
| IL315862A (he) | תכשירים מאפננים אנגיוטנסינוגן ושיטות לשימוש בהם | |
| IL325552A (he) | הרכבים ושיטות לשימוש בתצמידי נוגדנים-אוליגונוקליאוטידים ממוקדי- prkag2 | |
| IL316049A (he) | תכשירי רוקחות של מוסונטוזומאב ושיטות לשימוש | |
| EP4415690A4 (en) | COMPOSITIONS AND PROCEDURES FOR THE DISPENSING OF FUNDS | |
| IL306032A (he) | הרכבים של solabegron במיקרוניזציה ושיטות שימוש | |
| ES3054109T3 (en) | Certain chemical compositions and methods of use thereof | |
| IL312205A (he) | תרכובות Coxsackievirus B ושיטות לשימוש בהן | |
| IL317018A (he) | תכשירים לטיפול גני ושיטות השימוש בהם | |
| EP4352218A4 (en) | COMPOSITIONS AND METHODS FOR THE TARGETED RELEASE OF THERAPEUTICS | |
| IL324975A (he) | תכשירים מאפננים lrrk2 ושיטות לשימוש בהם | |
| IL324720A (he) | תכשירים מאפננים sod1 ושיטות לשימוש בהם | |
| GB202313643D0 (en) | Serping1-sarna compositions and methods of use |